Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.

ABSTRACT:

Background

Sarcoma is a highly heterogeneous malignancy with a poor prognosis. Although chemotherapy and targeted therapy have improved the prognosis to some extent, the efficacy remains unsatisfactory in some patients. The efficacy and safety of immunotherapy in sarcoma need further evaluation.

Methods

We conducted a two-center study of sarcoma patients receiving PD-1 immunotherapy at Tianjin Medical University Cancer Institute and Hospital and Henan Provincial Cancer Hospital. The treatment regimens included PD-1 inhibitor monotherapy and combination therapy based on PD-1 inhibitors. The observed primary endpoints were median progression-free survival (mPFS) and median overall survival (mOS). Survival curves were compared using the Kaplan-Meier method.

Results

A tot

SUBMITTER: Liao Z 

PROVIDER: S-EPMC10995229 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature